ConductScience.org, home

Paper41787239

Efficacy of Ublituximab in People with Highly Active Relapsing Multiple Sclerosis.

Hartung HP and 12 others. Neurol Ther, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Efficacy of Ublituximab in People with Highly Active Relapsing Multiple Sclerosis. Papers, record 41787239. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41787239

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Efficacy of Ublituximab in People with Highly Active Relapsing Multiple Sclerosis.
PubMed
Journal
Neurol Ther
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-13
PubMed

Authors13

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Hartung HPHans-Peter
2Robertson DDerrick
3Steinman LLawrence
4Arnold DLDouglas L
5Qian PPeiqing
6Wray SSibyl
7Fox EEdward
8Garner CAChristopher A
9Xu YYihuan
10Mok KKoby
11Gocke AAnne
12Cree BACBruce A C
13Alvarez EEnrique

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Trials2

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT03277248Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)Derived from the trialYesClinicalTrials.gov
NCT03277261Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )Derived from the trialYesClinicalTrials.gov

Download CSV of trials

References48

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
126121423Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis.Curr Med Res Opin2015https://conductscience.org/library/papers/26121423PubMed
236452173Rebaseline no evidence of disease activity (NEDA-3) as a predictor of long-term disease course in a Norwegian multiple sclerosis population.Front Neurol2022https://conductscience.org/library/papers/36452173PubMed
334398221Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies.JAMA Neurol2021https://conductscience.org/library/papers/34398221PubMed
439626127Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis: The Phase IIIb ENSEMBLE 4-Year, Single-Arm, Open-Label Trial.Neurology2024https://conductscience.org/library/papers/39626127PubMed
529609506Ublituximab for the treatment of CD20 positive B-cell malignancies.Expert Opin Investig Drugs2018https://conductscience.org/library/papers/29609506PubMed
634373345Prognostic Accuracy of NEDA-3 in Long-term Outcomes of Multiple Sclerosis.Neurol Neuroimmunol Neuroinflamm2021https://conductscience.org/library/papers/34373345PubMed
732530366Aggressive multiple sclerosis (2): Treatment.Mult Scler2020https://conductscience.org/library/papers/32530366PubMed
838112646Clinical and radiological consequences of delayed therapy escalation in patients with relapsing-remitting multiple sclerosis.Neurol Neurochir Pol2024https://conductscience.org/library/papers/38112646PubMed
930300457Multiple sclerosis - a review.Eur J Neurol2019https://conductscience.org/library/papers/30300457PubMed
1037851189Multiple sclerosis: time for early treatment with high-efficacy drugs.J Neurol2024https://conductscience.org/library/papers/37851189PubMed
1134220694Early High Efficacy Treatment in Multiple Sclerosis Is the Best Predictor of Future Disease Activity Over 1 and 2 Years in a Norwegian Population-Based Registry.Front Neurol2021https://conductscience.org/library/papers/34220694PubMed
1236969208B cell targeted therapies in inflammatory autoimmune disease of the central nervous system.Front Immunol2023https://conductscience.org/library/papers/36969208PubMed
1340619726Early Intensive Versus Escalation Approach: Ten-Year Impact on Disability in Relapsing Multiple Sclerosis.Ann Clin Transl Neurol2025https://conductscience.org/library/papers/40619726PubMed
1436001711Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.N Engl J Med2022https://conductscience.org/library/papers/36001711PubMed
1530820738Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis.J Neurol2019https://conductscience.org/library/papers/30820738PubMed
1629686116
Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
Neurology2018https://conductscience.org/library/papers/29686116PubMed
1733091175Role of B Cells in Multiple Sclerosis and Related Disorders.Ann Neurol2021https://conductscience.org/library/papers/33091175PubMed
1835217934Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing-Remitting Multiple Sclerosis After Fingolimod Withdrawal.Neurotherapeutics2022https://conductscience.org/library/papers/35217934PubMed
1926136751Antigen Presentation, Autoantigens, and Immune Regulation in Multiple Sclerosis and Other Autoimmune Diseases.Front Immunol2015https://conductscience.org/library/papers/26136751PubMed
2032710396Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study.CNS Drugs2020https://conductscience.org/library/papers/32710396PubMed

See all 48 referencesDownload CSV of references

Drugs2

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
UBLITUXIMABCHEMBL2108354Derived from the trial2https://conductscience.org/library/drugs/CHEMBL2108354ChEMBL
TERIFLUNOMIDECHEMBL973Derived from the trial2https://conductscience.org/library/drugs/CHEMBL973ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • Cited by
  • Genes
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41787239

GET https://conductscience.org/api/papers/v1/41787239/references?page=2